Top

Published in:

01-11-2020 | Atrial Fibrillation | Letter to the Editor

Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis

Authors: Chiara Kessler, Hans Stricker, Daniela Demundo, Luigia Elzi, Rita Monotti, Giorgia Bianchi, Michael Llamas, Luca Spinedi, Davide Rossi, Alessandro Felice Chiesa, Alberto Pagnamenta, Marco Conti, Gabriele Casso, Elisa Stoira, Elisa Valenti, Giuseppe Colucci, Georg Stussi, Bernhard Gerber, Marco Previsdomini

Published in: Journal of Thrombosis and Thrombolysis | Issue 4/2020

Excerpt

To the editor …

Available only for authorised users

Connors JM, Levy JH (2020) COVID-19 and its implications for thrombosis and anticoagulation. Blood. https://doi.org/10.1182/blood.2020006000CrossRefPubMedPubMedCentral

Levi M, Thachil J, Iba T, Levy JH (2020) Coagulation abnormalities and thrombosis in patients with COVID-19. Lancet Haematol 7(6):e438–e440. https://doi.org/10.1016/S2352-3026(20)30145-9CrossRefPubMedPubMedCentral

Cui S, Chen S, Li X, Liu S, Wang F (2020) Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia. J Thromb Haemost 18(6):1421–1424. https://doi.org/10.1111/jth.14830CrossRefPubMed

Middeldorp S, Coppens M, van Haaps TF, Foppen M, Vlaar AP, Muller MCA, Bouman CCS, Beenen LFM, Kootte RS, Heijmans J, Smits LP, Bonta PI, van Es N (2020) Incidence of venous thromboembolism in hospitalized patients with COVID-19. J Thromb Haemost. https://doi.org/10.1111/jth.14888CrossRefPubMedPubMedCentral

Bikdeli B, Madhavan MV, Jimenez D, Chuich T, Dreyfus I, Driggin E, Nigoghossian C, Ageno W, Madjid M, Guo Y, Tang LV, Hu Y, Giri J, Cushman M, Quere I, Dimakakos EP, Gibson CM, Lippi G, Favaloro EJ, Fareed J, Caprini JA, Tafur AJ, Burton JR, Francese DP, Wang EY, Falanga A, McLintock C, Hunt BJ, Spyropoulos AC, Barnes GD, Eikelboom JW, Weinberg I, Schulman S, Carrier M, Piazza G, Beckman JA, Steg PG, Stone GW, Rosenkranz S, Goldhaber SZ, Parikh SA, Monreal M, Krumholz HM, Konstantinides SV, Weitz JI, Lip GYH (2020) COVID-19 and thrombotic or thromboembolic disease: implications for prevention, antithrombotic therapy, and follow-up. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2020.04.031CrossRefPubMedPubMedCentral

Tang N, Bai H, Chen X, Gong J, Li D, Sun Z (2020) Anticoagulant treatment is associated with decreased mortality in severe coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 18(5):1094–1099. https://doi.org/10.1111/jth.14817CrossRefPubMed

Klok FA, Kruip M, van der Meer NJM, Arbous MS, Gommers D, Kant KM, Kaptein FHJ, van Paassen J, Stals MAM, Huisman MV, Endeman H (2020) Incidence of thrombotic complications in critically ill ICU patients with COVID-19. Thromb Res. https://doi.org/10.1016/j.thromres.2020.04.013CrossRefPubMedPubMedCentral

Llitjos JF, Leclerc M, Chochois C, Monsallier JM, Ramakers M, Auvray M, Merouani K (2020) High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients. J Thromb Haemost. https://doi.org/10.1111/jth.14869CrossRefPubMedPubMedCentral

Schulman S, Kearon C, Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis (2005) Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost 3(4):692–694. https://doi.org/10.1111/j.1538-7836.2005.01204.xCrossRef

10.

Kearon C, Akl EA, Comerota AJ, Prandoni P, Bounameaux H, Goldhaber SZ, Nelson ME, Wells PS, Gould MK, Dentali F, Crowther M, Kahn SR (2012) Antithrombotic therapy for VTE disease: antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 141(2 Suppl):e419S–e496S. https://doi.org/10.1378/chest.11-2301CrossRefPubMedPubMedCentral

11.

PROTECT Investigators for the Canadian Critical Care Trials Group and the Australian and NewZealand Intensive Care Society Clinical Trials Group, Cook D, Meade M, Guyatt G, Walter S, Heels-Ansdell D, Warkentin TE, Zytaruk N, Crowther M, Geerts W, Cooper DJ, Vallance S, Qushmaq I, Rocha M, Berwanger O, Vlahakis NE (2011) Dalteparin versus unfractionated heparin in critically ill patients. N Engl J Med 364(14):1305–1314. https://doi.org/10.1056/NEJMoa1014475CrossRef

12.

Wichmann D, Sperhake JP, Lutgehetmann M, Steurer S, Edler C, Heinemann A, Heinrich F, Mushumba H, Kniep I, Schroder AS, Burdelski C, de Heer G, Nierhaus A, Frings D, Pfefferle S, Becker H, Bredereke-Wiedling H, de Weerth A, Paschen HR, Sheikhzadeh-Eggers S, Stang A, Schmiedel S, Bokemeyer C, Addo MM, Aepfelbacher M, Puschel K, Kluge S (2020) Autopsy findings and venous thromboembolism in patients with COVID-19. Ann Intern Med. https://doi.org/10.7326/M20-2003CrossRefPubMedPubMedCentral

13.

Varga Z, Flammer AJ, Steiger P, Haberecker M, Andermatt R, Zinkernagel AS, Mehra MR, Schuepbach RA, Ruschitzka F, Moch H (2020) Endothelial cell infection and endotheliitis in COVID-19. Lancet 395(10234):1417–1418. https://doi.org/10.1016/S0140-6736(20)30937-5CrossRefPubMedPubMedCentral

14.

Ackermann M, Verleden SE, Kuehnel M, Haverich A, Welte T, Laenger F, Vanstapel A, Werlein C, Stark H, Tzankov A, Li WW, Li VW, Mentzer SJ, Jonigk D (2020) Pulmonary vascular endothelialitis, thrombosis, and angiogenesis in Covid-19. N Engl J Med. https://doi.org/10.1056/NEJMoa2015432CrossRefPubMedPubMedCentral

15.

World Health Organization (2020). Clinical Management of COVID-10 - Interim guidance, 27 May 2020 WHO, Geneva. Report available at https://apps.who.int/iris/handle/10665/332196. Accessed 16 June 2020

Title: Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis
Authors: Chiara Kessler
Hans Stricker
Daniela Demundo
Luigia Elzi
Rita Monotti
Giorgia Bianchi
Michael Llamas
Luca Spinedi
Davide Rossi
Alessandro Felice Chiesa
Alberto Pagnamenta
Marco Conti
Gabriele Casso
Elisa Stoira
Elisa Valenti
Giuseppe Colucci
Georg Stussi
Bernhard Gerber
Marco Previsdomini
Publication date: 01-11-2020
Publisher: Springer US
Keywords: Atrial Fibrillation
Acute Respiratory Distress-Syndrome
COVID-19
Enoxaparin
Published in: Journal of Thrombosis and Thrombolysis / Issue 4/2020
Print ISSN: 0929-5305
Electronic ISSN: 1573-742X
DOI: https://doi.org/10.1007/s11239-020-02244-y

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Bleeding prevalence in COVID-19 patients receiving intensive antithrombotic prophylaxis

Excerpt

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Excerpt

Please log in to get access to this content

Other articles of this Issue 4/2020

Thromboprophylaxis: balancing evidence and experience during the COVID-19 pandemic

The Impact of platelet–fibrin clot strength on occurrence and clinical outcomes of peripheral artery disease in patients with significant coronary artery disease

Differentiating biochemical from clinical heparin resistance in COVID-19

Venous thromboembolism in critically ill COVID-19 patients receiving prophylactic or therapeutic anticoagulation: a systematic review and meta-analysis

Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis

Argatroban therapy for heparin-induced thrombocytopenia in a patient with coronavirus disease 2019

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page